<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04195984</url>
  </required_header>
  <id_info>
    <org_study_id>M-valve-2018-06</org_study_id>
    <nct_id>NCT04195984</nct_id>
  </id_info>
  <brief_title>Mi-thos® Transcatheter Mitral Valve Replacement Study</brief_title>
  <official_title>Evaluation of the Efficacy and Safety of the Mi-thos® Transcatheter Mitral Valve Replacement System in Patients With Severe Mitral Valve Disease at High Surgical Risk.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai NewMed Medical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai NewMed Medical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and performance of the Mi-thos® Mitral Heart Valve with the Mi-thos®&#xD;
      Transcatheter Delivery System.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Mi-thos® study is an multicenter, single-arm, prospective, safety and performance&#xD;
      clinical study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 25, 2021</start_date>
  <completion_date type="Anticipated">January 2027</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from all-cause mortality</measure>
    <time_frame>1 year</time_frame>
    <description>All-cause mortality after TMVR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from all-cause mortality</measure>
    <time_frame>30 days, 6months, 2-5 years</time_frame>
    <description>All-cause mortality after TMVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe adverse event rate</measure>
    <time_frame>30 days, 6months, 1 year, 2-5 years</time_frame>
    <description>Severe adverse events rate after TMVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA Heart Function Rating</measure>
    <time_frame>30 days, 6months, 1 year, 2-5 years</time_frame>
    <description>NYHA Heart Function Rating after TMVR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kansas City Cardiomyopathy score</measure>
    <time_frame>30 days, 6months, 1 year, 2-5 years</time_frame>
    <description>Kansas City Cardiomyopathy score after TMVR</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">122</enrollment>
  <condition>Mitral Valve Regurgitation</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter mitral valve replacement with the Mi-thos® valve and transcatheter delivery system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mi-thos® valve and transapical delivery system</intervention_name>
    <description>Transcatheter mitral valve replacement system</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Severe mitral valve regurgitation ≥ 3+;&#xD;
&#xD;
          -  High surgical risk fot open mitral valve surgery;&#xD;
&#xD;
          -  Age ≥ 65 years old;&#xD;
&#xD;
          -  Life expectancy &gt; 12 months;&#xD;
&#xD;
          -  As assessed by multidisciplinary cardiac team, patients who are not eligible for&#xD;
             surgery;&#xD;
&#xD;
          -  Patients sign an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous cardiac mitral valve surgery;&#xD;
&#xD;
          -  Active infections requiring antibiotic therapy;&#xD;
&#xD;
          -  Clinically significant untreated Coronary Artery Disease (CAD);&#xD;
&#xD;
          -  Pulmonary hypertension （Pulmonary systolic pressure &gt; 70 mmHg）;&#xD;
&#xD;
          -  Patients with severe right heart failure;&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;25%;&#xD;
&#xD;
          -  Diagnosis of hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive&#xD;
             pericarditis;&#xD;
&#xD;
          -  Dialysis patient;&#xD;
&#xD;
          -  Patients with severe coagulopathy;&#xD;
&#xD;
          -  Patients with contraindications to anticoagulant drugs;&#xD;
&#xD;
          -  Patients with stroke or transient ischemic within 30 days;&#xD;
&#xD;
          -  Echocardiography found any intracardiac mass, left ventricle or atrial thrombus;&#xD;
&#xD;
          -  Patients who require surgery or interventional therapy for other valvular lesions;&#xD;
&#xD;
          -  Patients with severe macrovascular disease requiring surgical treatment;&#xD;
&#xD;
          -  Patients with more than 70% of carotid stenosis;&#xD;
&#xD;
          -  To be allergic to contrast agents, nickel-titanium memory alloys or bovine-derived&#xD;
             products;&#xD;
&#xD;
          -  Patients with severe neurological disorders affecting cognitive ability;&#xD;
&#xD;
          -  Patients with severe thoracic deformities.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wang chunsheng, Chief</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Zhongshan Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wang chunyang, CRA</last_name>
    <phone>(86)-21-20788668</phone>
    <email>cywang@newmed.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xie xuyang, c</last_name>
    <phone>(86)-21-20788668</phone>
    <email>xyxie@newmed.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Fuwai hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zheng zhe, Chief</last_name>
      <phone>(+86)010-88396051</phone>
      <email>zhengzhe@fuwai.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wang chunsheng, Chief</last_name>
      <phone>(86)021-64041990</phone>
      <phone_ext>2512</phone_ext>
      <email>cswang@medmail.com.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xijing hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yang jian, Chief</last_name>
      <phone>(+86)029-84774114</phone>
      <email>yangjian@fmmu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 10, 2019</study_first_submitted>
  <study_first_submitted_qc>December 10, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 12, 2019</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

